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Dear Editor,
The very interesting Commentary “Clinical ethics and the role of clinical ethics com-
mittees: proposal for a revival” by Petrini and Ricciardi [1], must be commended for 
addressing the relevant issue of “clinical ethics”, the role of current and future ethics 
committees, and, in particular, for drawing attention to the CNB (Comitato Nazionale 
di Bioetica – Italian Bioethics Committee) influential document on the topic [2].
Still, considering the importance of the matter, we would like to add some further 
remarks. The first document defining the duties of ethics committees in Italy concerned 
only the assessment of clinical trials and biomedical research in general [3]. The legisla-
tor started considering ethical aspects, in addition to those involved in controlled clini-
cal trials and biomedical research on human beings, only since the Ministerial Decree 
dated 12 May 2006, Article 1, paragraph 3 [4]. The same point was later reiterated with 
the Ministerial Decree dated 8 February 2013 [5]. 
Despite that, until now ethics committees are mostly engaged in the assessment of 
clinical trials and biomedical researches. This means that they can mostly consider 
those requirements that validate a research from a scientific point of view, contextual-
izing them in the ethical framework of bioethics’ evolution since the Belmont Report 
and the due observance of the principles of beneficence, autonomy, and justice [6], for-
mally reasserted by the Helsinki Declaration [7] and the Oviedo Convention [8]. Such 
requisites mainly consists of: i) the relevance of the clinical question and the pertinence 
of primary and secondary outcomes to be recorded on an adequate target population; 
ii) the accordance with scientific methodology and, consequently, the appropriate clini-
cal and statistical planning of the study; iii) the benefit/risk ratio for the human beings 
involved; iv) finally, the procedures of obtaining informed consent, not limited to the 
adequacy and completeness of the written text.
Current ethics committees also play an important role in the evaluation of “obser-
vational studies”. They must primarily ascertain the actual observational nature of the 
proposed studies, thus avoiding the enrollment of unaware subjects in an experimental 
study. Therefore, they must also guarantee the accordance of study procedures to “the 
usual standard of care”, in order to avoid additional burdens for the patient. Finally, 
issues of privacy and adequate information to subjects enrolled must be considered. 
This last point is sometimes quite problematic since, in non-interventional studies, the 
information could be often deemed non-essential and thus it is sometimes inaccurate 
or even missing altogether. 
One should finally remember the role of the ethics committees in the approval of the 
therapeutic use of a medical product subjected to clinical trial, the so-called expanded 
access/compassionate use, according the Ministerial Decree dated 8 May 2003 [9], 
recast and replaced by Ministerial Decree dated 7 September 2017 [10]. 
In addition, current ethics committees have often undertaken educational and train-
ing tasks, planning seminars and workshops, mainly focused on ethical topics [11]. 
In light of the above, recent proposals for the establishment, along with the already 
existing research ethics committees, of “new ethics committees” devoted to “clinical 
ethics” shall be welcomed. 
However, it cannot be denied that the institution of such “new ethics committees” 
raises some concerns, especially considering the problems with respect to: i) their actual 
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composition; ii) the expertise that shall be required for their members; iii) their interac-
tion with Legal Medicine Services in hospitals and health care institutions; iv) the cost 
burdens and the problem of who shall take upon itself those burdens; v) their effective 
independence from the institution that provides for the payments of the members; vi) 
the extent of their dissemination (regional, with no knowledge of the local reality, or 
local, at each hospital with tremendous economic and organizational demands).
In our opinion, with respect to the issue of the composition and structure of the new 
ethics committees, it is extremely important to openly address the very specific recom-
mendation of the CNB regarding the multidisciplinary and pluralistic character of clini-
cal ethics consultation, which “is exclusive task of the committees and must be provided 
by the committee in its entirety” [2].  The CNB thus disavows the individual ethics 
consultant model and reiterates the need for ethics opinions to be formed jointly in the 
deliberative setting of clinical ethics committees. This setting provides a wealth of dif-
ferent perspectives and the varied, complementary qualifications of their members, and 
acknowledges, at the same time, the need to safeguard the physician/patient/relatives or 
health care team/patient/relatives relationship, avoiding any delegation to the “expert” 
outside of the profession of the moral responsibility that is integral to the medical and 
healthcare professions themselves.
One last comment concerns the inclusion of an “epidemiologist” in the clinical ethics 
committees. In addition, we suggest that also a “clinical epidemiologist or a biostatisti-
cian” should be included, for her/his specific expertise in the evidence based medicine 
(EBM), focused on the evaluation of the evidence of health interventions, which is 
crucial to assess their appropriateness and therefore their ethical soundness at the clini-
cal level.
These are just two instances of a complex of thorny issues that seem far from being 
resolved, especially if one considers the ongoing debate in literature about the pros and 
cons of different models of clinical ethics consultation [11] and the long gestational and 
finalization process of the CBN document [2]. 
As a matter of fact, in the beginning, clinical ethics committees and clinical ethics 
consultants were allotted the tasks of the ethical analysis of particularly problematic 
clinical cases; the drawing up of recommendations and guidelines to address recur-
rent ethical problems; the promotion and management of training programs to increase 
ethical awareness among healthcare workers [12]. These actions should be primarily 
addressed to clinical staffs and place the ethicists “in a role supportive of the clinical 
practitioners”, helping them to “make explicit the values inherent in their decisions”, 
even undertaking the more committed role of personal counsellors. 
In our opinion, this role should not escalate to a more substantial patients advocacy, 
which places the ethicist “between the practitioner and his context of performance”, 
interfering with the health care professionals’ attention and performance [13]. This 
kind of interference, in the complex and unstable clinical setting, might also lead to “a 
replacement of the privacy of the doctor- patient relationship [13]”, a reduction of “the 
freedom to care and comfort in seeking cure”, and a potential risk “for ethical leverage 
through financial-legal consequences” [13]. A more positive role of the ethicist, besides 
offering her/his expertise in the ethical analysis of particularly problematic clinical cases 
in multidisciplinary committees, could be the educational one. Given the rather desul-
tory and mainly abstract training in Bioethics that prospective physicians and health-
care providers receive in Italian universities, an effective interaction with clinical ethics 
committees and consultants could enhance in clinical staff, physicians, and, especially, 
physicians undergoing specialized training, the ethical expertise that is part-and-parcel 
of their professional responsibility. This is particularly true in such areas as intensive 
care unit, coronary care unit, stroke unit, oncology [14], and paediatrics [15], where 
more often medical and health care personnel confront complex and dramatic moral 
dilemmas [16].
Finally, given the importance of validating medical actions, and generally all kind of 
actions taken in medical settings, according to EBM, ethical consultation should be 
critically evaluated following a standardized approach [17]. It might be an approach 
pragmatically oriented on the outcomes, that nevertheless allows the assessment of the 
distinction between the interactions linked to the usual medical practice and the further 
contribution given by the ethical consultation. Even if this kind of research is mainly 
qualitative and raises formidable methodological problems, such as those regarding the 
control group and “sham interview”, it is desirable to strive to obtain answers as objec-
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tive as possible, especially taking into account the investments that the introduction of 
such a practice in the public health involves.
Elisa Buzzi and Bruno Mario Cesana 
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